Alpha Teknova, Inc. TKNO
Regular-session close
After hours · Nov 19, 4:27 PM ET
- YTD
- +105.53%
- 1 year
- +76.70%
5D -0.25 (-3.06%)
- Market cap
- 491.27M
- Revenue (ttm)
- 36.35M
- Profit margin
- -87.17%
- EPS (ttm)
- -0.30
- Shares out
- 53.31M
- Forward P/E
- -19.69
- YTD return
- +105.53%
- 1-year return
- +76.70%
- 50-day average
- 7.11
- Volume
- 266.84K
- Avg volume
- 437.87K
- Open
- 7.93
- Previous close
- 7.88
- Day's range
- 7.69 – 8.12
- 52-week range
- 1.91 – 9.48
- Beta
- 0.36
- Analysts
- Buy
- Price target
- 8.00 (+2.4%)
Key statistics
- 200-day average
- 3.96
- Enterprise value
- 399.47M
- Price / sales
- 11.26
- Price / book
- 4.56
- Revenue growth
- 17.20%
- Free cash flow
- -4.99M
- Total cash
- 31.69M
- Total debt
- 30.59M
- Return on equity
- -33.90%
- Short % of float
- 1.33%
Fundamental scorecard
7 of 25 checks passed on TKNO’s reported financials
7of 25 checks passed
- Value 0 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -0.15 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.13 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.20 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 11, 2024 | Dec 1, 2023 | -0.23 | -0.22 | +0.01 | +4.35% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 10, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| May 14, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| Mar 12, 2024 | BTIG | down | Buy | Neutral |
| Jul 12, 2023 | Keybanc | init | — | Sector Weight |
| Aug 11, 2022 | Stephens & Co. | main | — | Overweight |
| Mar 16, 2022 | Stephens & Co. | main | — | Overweight |
About Alpha Teknova, Inc.
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- teknova.com
News
Wall Street Analysts Think Alpha Teknova (TKNO) Could Surge 26.41%: Read This Before Placing a Bet
Alpha Teknova (NASDAQ:TKNO) versus Charles River Laboratories International (NYSE:CRL) Critical Analysis
Alpha Teknova Q3 2026 Earnings Call Transcript Alpha Teknova Raises FY2026 Sales Guidance from $45.000M-$47.000M to $46.000M-$48.000M vs $46.058M Est
Alpha Teknova Q3 EPS $(0.06) Beats $(0.07) Estimate, Sales $12.704M Beat $11.639M Estimate
Tesla, Lam Research, Rollins And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings
Dow Gains Over 100 Points; AT&T Earnings Top Views
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on TKNO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEMSKI MARTHA J. | Director | Stock Award(Grant) | Jun 25, 2024 | 20,000 |
| GELHAUS KEN | Officer | Purchase | Nov 29, 2023 | 22,924 |
| GUNSTREAM STEPHEN | Chief Executive Officer | Purchase | Jul 11, 2024 | 243,497 |
| HOOD LISA | Officer | Sale | Jun 12, 2023 | 33,834 |
| LOWELL MATTHEW | Chief Financial Officer | Purchase | Jul 11, 2024 | 128,376 |
| MACKOWSKI J MATTHEW | Director | Purchase | Sep 18, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Balyasny Asset Management LLC | 1.88% | 1,000,090 | 7.68M | Sep 29, 2024 |
| Millennium Management Llc | 1.38% | 737,215 | 5.66M | Sep 29, 2024 |
| Vanguard Group Inc | 1.05% | 560,860 | 4.31M | Sep 29, 2024 |
| Roubaix Capital, LLC | 0.78% | 416,416 | 3.20M | Sep 29, 2024 |
| Schonfeld Strategic Advisors Llc | 0.69% | 366,400 | 2.81M | Sep 29, 2024 |
| Conestoga Capital Advisors, LLC | 0.57% | 305,129 | 2.34M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.57% | 303,047 | 2.33M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.45% | 240,629 | 1.85M | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.21% | 110,000 | 844.80K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.14% | 75,363 | 578.79K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.09% | 47,379 | 363.87K | Oct 30, 2024 |
| Conestoga Discovery Fund | 0.06% | 30,716 | 235.90K | Sep 29, 2024 |
